We congratulate our colleagues and co-first authors Dr. Carsten Riether and Dr. Christian Schürch from the Ochsenbein Lab (Department of Clinical Research, University of Bern) on their outstanding publication in the highly ranked journal Science Translational Medicine. In thier study they present evidence that a combined therapy using Imatinib, a tyrosine kinase inhibitor, together with a CD70 blocking antibody is more efficient for the treatment of chronic myelogenous leukemia (CML) than the conventional approach with Imatinib alone. Find out more about their study here and here.